- Molecular NameFosinopril
- SynonymFosinopril Sodium
- Weight563.672
- Drugbank_IDDB00492
- ACS_NO98048-97-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.83
- pka4.5
- LogD (pH=7, predicted)1.2
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-1.03
- LogSw (predicted, AB/LogsW2.0)0.04
- Sw (mg/ml) (predicted, ACD/Labs)0.09
- No.of HBond Donors1
- No.of HBond Acceptors8
- No.of Rotatable Bonds15
- TPSA120.02
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn angiotensin converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of chronic heart failure. Fosinopril is the only phosphonate-containing ACE inhibitor marketed.
- Absorption_value35.0
- Absorption (description)36% of an orally administered dose of fosinopril is absorbed.
- Caco_2N/A
- Bioavailability34.0
- Protein binding95.0
- Volume of distribution (VD)1.525 L/kg (Caucasian); 0.074 L/kg (Chinese)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is rapidly and completely hydrolysed to fosinoprilat, a p-hydroxy metabolite and a glucuronide conjugate of fosinoprilat. Metabolism occurs by esterases in gastro-intestinal mucosa and in the liver.
- Half life11.5 h in healthy volunteers; 14 h in patients with renal impairment.
- ExcretionThe metabolites are excreted in urine and faeces via bile. During 96 h post-intravenous administration, 90% of a dose is recovered, 44% in urine and 46% in faeces. For oral administration, however, 13 to 16% is recovered in urine and 73 to 78% in faeces. The drug has also been detected in breast milk.
- Urinary ExcretionN/A
- CleranceFosinopril, body clearance, 1.55 to 2.35 L/h; fosinoprilat, 26 to 39 mL/min.
- ToxicityHypotension.
- LD50 (rat)N/A
- LD50 (mouse)N/A